Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.34 |
| ▸ | NAT1 | P18440 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201440 | 0.80 | AURKA (0.34) | AURKANAT1KDRCDK1CA12 | |
| SCHEMBL3835742 | 0.77 | AURKA (0.37) | AURKAKDRCDK1CA12CA9 | |
| SCHEMBL3840001 | 0.75 | PARP10 (0.36) | AURKAKDRCA12CA9 | |
| SCHEMBL21050803 | 0.74 | AURKA (0.40) | AURKAKDRCDK1CA12CA9 | |
| SCHEMBL3835512 | 0.72 | KDR (0.41) | AURKAKDRCA12CA9 | |
| SCHEMBL3837295 | 0.70 | AURKA (0.37) | AURKAKDRCA12CA9 | |
| SCHEMBL3836901 | 0.70 | GRM5 (0.37) | AURKAKDRCA12CA9 | |
| SCHEMBL31158957 | 0.70 | GRM5 (0.37) | AURKAKDRCA12CA9 | |
| SCHEMBL5311516 | 0.70 | AURKA (0.37) | AURKAKDRCDK1CA12CA9 | |
| SCHEMBL10200892 | 0.70 | AURKA (0.44) | AURKAKDRCDK1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | AURKA 3106/4885NAT1 282/4885KDR 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.